Stevanato Group(US:STVN)2026-03-04 21:10Revenue Growth - Total Company revenue increased by 9% at constant currency and 7% on a reported basis for FY 2025, driven by strong growth in the Biopharmaceutical and Diagnostic Solutions Segment [15]. - High-Value Solutions (HVS) revenue grew by 29% year-over-year in 2025, contributing significantly to margin expansion [15]. - Revenue from GLP1s accounted for approximately 19% to 20% of total Company revenue, growing over 50% compared to 2024 [21]. - Q4 2025 revenue reached €346 million, a 31% increase year-over-year, with HVS representing 49% of total revenue [37]. - The Company expects continued growth in the GLP market, driven by various factors including biosimilar launches and next-gen incretins [21]. - FY 2026 revenue guidance is set between €1.260 billion and €1.290 billion, implying a growth rate of 6% to 9% [46]. - The company plans to achieve a reported revenue of €1,290.0 million for 2026, with an adjusted EBITDA guidance of €331.8 million [79]. Profitability and Margins - Adjusted EBITDA increased by 7% to €97.7 million, with an adjusted EBITDA margin of 28.2% [38]. - Adjusted EBITDA for FY 2025 was €287.4 million, representing an 18.8% increase compared to the previous year [64]. - The adjusted operating profit margin for FY 2025 was 17.7%, up from 16.2% in FY 2024, reflecting improved operational efficiency [65]. - Gross profit margin for the BDS Segment improved to 31.6%, driven by a favorable mix of HVS and operational improvements [41]. Capital Expenditures and Cash Flow - Free cash flow for fiscal year 2025 was €18.4 million, with cash from operating activities at €286.1 million, exceeding expectations due to better performances in TWC and timing of capital expenditures [45]. - Total capital expenditures for FY 2026 are projected to be between €270 million and €290 million, with net customer contributions reducing capex to between €240 million and €260 million [49]. - The addition to property, plant, and equipment for the year ended December 31, 2025, was €283.6 million, reflecting an increase of €8.0 million from the previous year [74]. - The company recorded cash flow from operating activities of €286.1 million for the year ended December 31, 2025, compared to €155.8 million for the previous year [78]. Customer Demand and Market Trends - In 2025, the number of customers ordering High-Value PFS increased by 40%, indicating strong market demand [21]. - HVS revenue reached a record level of €171.4 million, accounting for 56% of segment revenue, with a year-over-year growth of 31% driven by strong demand for high-value Nexa® syringes [44]. - The company has over 9,000 injectable drug products in the global pipeline, with more than 60% being biologics, indicating strong future growth potential [55]. Segment Performance - The Engineering Segment experienced a revenue decline, with Q4 2025 revenue at €39 million, down from €51 million in Q4 2024 [42]. - Revenue decreased by 23% year-over-year to €39.4 million, primarily due to lower sales from glass converting and assembly lines, partially offset by growth in pharma visual inspection [43]. Financial Position - As of December 31, 2025, the net debt was €337.7 million, slightly higher than €335.0 million as of December 31, 2024 [76]. - Capital employed as of December 31, 2025, was €1,824.2 million, an increase from €1,739.4 million as of December 31, 2024 [72]. Tax and Start-up Costs - The tax rate for FY 2026 is expected to be approximately 26.8% [49]. - Start-up costs for new plants in Fishers, Indiana, and Latina, Italy, amounted to €3.8 million for Q4 2024 and €13.0 million for the full year 2024 [69]. - Restructuring and related charges for the year ended December 31, 2024, totaled €4.0 million, primarily related to employee costs [70].